Quibim: transforming medical imaging data into actionable predictions

Quibim is a deep-tech pioneering company in the field of medical imaging and Artificial Intelligence (AI), dedicated to revolutionizing the detection, diagnosis, and treatment of several clinical indications through advanced imaging analytics, with the ambition to transform imaging into a catalyst for precision health. Quibim’s vision is to leverage state-of-the-art AI technology to transform medical images into actionable, quantitative data that can improve patient outcomes and streamline clinical workflows in oncology/immunotherapy, rheumatology and neurology. The company designs pioneering tools that unlock imaging data to improve patient outcomes.  

The company counts on key assets to develop and validate AI-based solutions for cancer diagnosis:  

• Worldwide customer portfolio of hospitals in Spain, France, UK, Netherlands, Sweden, Italy, Poland, Mexico, Argentina, Israel, Japan, and others.  

• Quibim brings extensive regulatory validation experience from previous AI-based solutions in Oncology, such as QP-Prostate, QP-Brain, and QP-Liver, which has already received CE marking, UKCA and FDA approval. We are equipped with an internal regulatory group that specializes in navigating complex regulatory pathways and ensuring compliance with global standards.  

• Additionally, Quibim is committed to the highest standards of quality and security, adhering to ISO 9001 for quality management and ISO 27001 for data protection and Information Security Management Systems (ISMS). Quibim also fully complies with GDPR and HIPAA regulations.  

• Quibim has cultivated strong partnerships within the healthcare ecosystem, collaborating with leading pharmaceutical companies. Moreover, Quibim has led 100+ RWE studies and randomized controlled trials (RCT) with 10M+ images processed to date, and currently coordinates or participates in 9 EU projects 

• IP assets: Quibim’s proprietary innovations, technologies, and methods, are key to giving the company a competitive edge over competitors, protecting our cash flow generation for years, and attracting investors and partners. Eventually, also for revenue generation through licensing. 

• Computing infrastructure: Universal system for all AI workloads with high compute density, performance and flexibility to consolidate training, inference and analytics into a unified, easy-to-deploy AI infrastructure. A hybrid infrastructure based on local (NVIDIA DGX A100) and cloud (Microsoft Azure) computing will be used to guarantee training process optimization. 

• Expert Team: Quibim boasts a multidisciplinary team of experts in AI, Radiology, and Oncology, ensuring its solutions are both clinically relevant and technologically advanced.

 Quibim has firmly established itself as a leader in the development and validation of AI-based diagnostic tools tailored for medical practice, particularly in supporting the critical decision-making processes of oncologists and radiologists.